Cancer NetworkOriginal article
<![CDATA[Fixed-Duration Cevostamab Yields Durable Responses Off Therapy]]>
Data ReadoutpositivecevostamabPositive
AI Analysis
Summary
Cevostamab demonstrates durable responses in patients with multiple myeloma who achieve deep responses, allowing some patients to discontinue therapy while maintaining remission. Dr. Adam Cohen highlights the potential for long-term disease control with fixed-duration treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Fixed-duration cevostamab yields durable responses with patients maintaining remission off therapy
Importance:6/10
Sentiment:
0.75
cevostamabmultiple myelomafixed-duration therapydurable responseoff-therapy remission
Read the original article
Published by Cancer Network on August 4, 2026 8:00 PM